OC
ONCT

Oppenheimer & Co’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Oppenheimer & Co’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-8
Closed -$16K – 1481
2015
Q2 		$16K Hold
8
– – ﹤0.01% 1463
2015
Q1 		$7K Hold
8
– – ﹤0.01% 1479
2014
Q4 		$7K Hold
8
– – ﹤0.01% 1390
2014
Q3 		$7K Hold
8
– – ﹤0.01% 1410
2014
Q2 		$15K Hold
8
– – ﹤0.01% 1396
2014
Q1 		$16K Buy
8
+1
+14% +$2.49K ﹤0.01% 1393
2013
Q4 		$17K Hold
7
– – ﹤0.01% 1368
2013
Q3 		$20K Hold
7
– – ﹤0.01% 1303
2013
Q2 		$66K Buy
+7
New +$53.9K ﹤0.01% 1227

Other funds holding ONCT

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
FHA
First Horizon Advisors Memphis, Tennessee $3.85B AUM 16.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return

Oppenheimer & Co's ONCT Position: Q3 2015 in Review

Oppenheimer & Co sold out of Oncternal Therapeutics, Inc. Common Stock (ONCT) in Q3 2015, closing a stake of 8 shares — an estimated $16K sold.

Oppenheimer & Co first reported a position in ONCT in Q2 2013 and held it in 9 quarters. The position peaked at $66K in Q2 2013. 38 funds tracked by Wall St. Rank hold ONCT as of Q3 2015.

  • Oppenheimer & Co reported no remaining Oncternal Therapeutics, Inc. Common Stock position as of Q3 2015 after selling out during the quarter.
  • Oppenheimer & Co sold 8 Oncternal Therapeutics, Inc. Common Stock shares in Q3 2015, an estimated $16K.
  • Oppenheimer & Co first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q2 2013 and held it in 9 quarters.
  • Oppenheimer & Co's Oncternal Therapeutics, Inc. Common Stock position peaked at $66K in Q2 2013.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q3 2015.

Based on Oppenheimer & Co's 13F filing for Q3 2015, filed 13 Nov 2015.